Catalent Pharma Solutions has signed an agreement with Therachon AG, a Swiss biotechnology company focused on rare genetic diseases, to support preclinical and clinical development of TA-46, a novel protein addressing achondroplasia, which is the most common form of short-limbed dwarfism. Catalent Biologics has employed its proprietary GPEx technology to produce different protein variants for Therachon, allowing them to screen multiple molecules and subsequently select their clinical candidat...